National Mantle Cell Lymphoma Trial - Phase II Randomized Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma.

Trial Profile

National Mantle Cell Lymphoma Trial - Phase II Randomized Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2015

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Dec 2012 Additional lead trial centre identified as reported by United Kingdom Clinical Research Network.
    • 05 Nov 2009 Additional lead trial centre, trial locations identified as reported by United Kingdom Clinical Research Network record.
    • 05 Nov 2009 New source identified and integrated (United Kingdom Clinical Research Network).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top